SCHEMBL3206924

SCHEMBL3206924

FC(F)(F)c1cc(Br)c(Br)nn1

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
NT5E P21589 1/20 0.32
CA2 P00918 1/20 0.31
CHKA P35790 1/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21241509 0.77 CES2 (0.31) NT5E
SCHEMBL31522927 0.77 CA2 (0.38) NT5ECA2CHKAKDM4E
SCHEMBL16235040 0.77 CA2 (0.38) NT5ECA2CHKAKDM4E
SCHEMBL3221371 0.77 NT5E (0.30) NT5E
SCHEMBL3217372 0.73 KDM4E (0.35) KDM4E
SCHEMBL16064902 0.73 HPGD (0.31)
SCHEMBL30374282 0.67 HSP90AA1 (0.42) NT5ECA2CHKAKDM4E
SCHEMBL21596956 0.67 HSP90AA1 (0.42) NT5ECA2CHKAKDM4E
SCHEMBL13259534 0.65 NT5E (0.34) NT5ECA2CHKAKDM4E
SCHEMBL3295796 0.64 TRPV4 (0.48) NT5ECA2CHKAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109372175-A A kind of preparation method of mould proof plasterboard 嘉兴凯蒂市场营销策划有限公司 2019-02-22 CN claimed
CN-107654011-A A kind of preparation method of the mould proof plasterboard of modularization plaster tablet suspended ceiling 江山海维科技有限公司 2018-02-02 CN claimed
CN-109372175-A A kind of preparation method of mould proof plasterboard 嘉兴凯蒂市场营销策划有限公司 2019-02-22 CN disclosed
CN-109372175-A A kind of preparation method of mould proof plasterboard 嘉兴凯蒂市场营销策划有限公司 2019-02-22 CN disclosed
CN-107762031-A A kind of modularization plaster tablet suspended ceiling technique 江山海维科技有限公司 2018-03-06 CN disclosed
CN-107654011-A A kind of preparation method of the mould proof plasterboard of modularization plaster tablet suspended ceiling 江山海维科技有限公司 2018-02-02 CN disclosed
US-8906921-B2 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2014-12-09 US disclosed
US-8906921-B2 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2014-12-09 US disclosed
US-8906921-B2 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2014-12-09 US disclosed
EP-2148873-B1 4-ALKOXYPYRIDAZINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2012-08-29 EP disclosed
US-20100063058-A1 4-ALKOXYPYRIDAZINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2010-03-11 US disclosed
US-20100063058-A1 4-ALKOXYPYRIDAZINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2010-03-11 US disclosed
US-20100063058-A1 4-ALKOXYPYRIDAZINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2010-03-11 US disclosed
EP-2148873-A1 4-ALKOXYPYRIDAZINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2010-02-03 EP disclosed
WO-2008128995-A1 4-ALKOXYPYRIDAZINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-10-30 WO disclosed
WO-2008128995-A1 4-ALKOXYPYRIDAZINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063058-A1 4-ALKOXYPYRIDAZINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS DRD2, GRIN2C, GRIN2A NT5E 1781/4885CA2 3250/4885CHKA 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.